🟢 MetaVia is trading 8.5% up in pre-market; immediate reason remains unclear

MetaVia is trading at $1.29, up 8.45%, in pre-market on October 30, 2026; no clear company-specific catalyst is confirmed.

• Phase 1 DA-1726 data presentation at the November 4 Precision Liver Symposium was announced in coverage on October 28, but is not established as the reason for the gain.
• The supplied market context shows the Nasdaq Composite down 2.04% and the S&P 500 down 0.86%, a direction that does not explain MetaVia’s rise.